Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180037/S015

Venovo Venous Stent System

Bard Peripheral Vascular, Inc. · Decision date Jun 10, 2026

FDA DECISIONP180037/S015

What did the FDA decide?

FDA records P180037/S015 as a supplement to PMA P180037, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 10, 2026.

FDA approval order statement

changes to the packaging supplier's adhesive coating
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 10, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P180037/S015
Regulatory pathway
PMA supplement
Product code
QAN
Decision code
OK30
Decision date
Jun 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, iliac vein.

Product code
QAN
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180037/S015 received

    Application receipt date recorded by FDA.

  2. P180037/S015 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P180037. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code QAN

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Vascular, Inc.PMA supplementOct 30, 2026FDA
Medtronic Vascular, Inc.PMA supplementOct 16, 2026FDA
Philips Image Guided Therapy CorporationPMA supplementAug 26, 2026FDA
Medtronic Vascular, Inc.PMA supplementApr 27, 2026FDA
Cook Ireland, Ltd.PMA supplementApr 14, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bard Peripheral Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1625 W Third St., Tempe, AZ, 85281

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records